Answers are grounded in this paper and cite their sources.
Preclinical study reveals matairesinol monoglucoside reduces hepatitis B viral markers in murine liver cells, indicating its therapeutic promise via STING activation.
BACKGROUND: the urgent need for effective prevention and treatment strategies for hepatitis B virus (HBV) has driven extensive research into natural compounds. This study aims to explore the therapeutic potential of matairesinol monoglucoside (MMG) in the treatment of HBV infection. METHODS: anti-HBV effects were determined by pre-treating mice with MMG prior to AAV-HBV infection. RESULTS: MMG treatment significantly reduced the expression of HBV DNA, HBsAg, and HBeAg in both primary hepatocytes and Kupffer cells. Additionally, MMG enhanced the production of type I interferons (IFN-α and IFN-β) in both cell types. The knockout of STING diminished the effects of MMG on type I interferon production. Mechanistically, MMG was shown to modulate the STING-TBK1-IRF3 signaling axis, leading to increased IFN production. CONCLUSIONS: MMG shows promise as a potential therapeutic agent against HBV by targeting the STING signaling pathway.
No takes yet. Share an insight, caveat, or question.
Su et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: